Safety and tolerability in multidrug- and extensively drug-resistant tuberculosis patients exposed and not exposed to meropenem/clavulanate (MC)-containing regimens
| Total | MC-sparing regimen | MC-containing regimen | p-value | |
| Subjects | 264 | 168 | 96 | |
| Interruption of linezolid | 36/159 (22.6) | 13/69 (18.8) | 23/90 (25.6) | 0.32 |
| Interruption of linezolid due to adverse events | 25/139 (18.0) | 11/57 (19.3) | 14/82 (17.1) | 0.74 |
| Adverse events presumably due to linezolid | 50/145 (34.5) | 13/56 (23.2) | 37/89 (41.6) | 0.02 |
| Anaemia | 28/166 (16.9) | 8/74 (10.8) | 20/92 (21.7) | 0.06 |
| Leukopenia | 9/169 (5.3) | 5/78 (6.4) | 4/91 (4.4) | 0.56 |
| Thrombocytopenia | 11/148 (7.4) | 0/57 (0.0) | 11/91 (12.1) | 0.007 |
| Peripheral neuropathy | 41/161 (25.5) | 12/70 (17.1) | 29/91 (31.9) | 0.03 |
| Gastrointestinal disorder | 22/151 (14.6) | 14/60 (23.3) | 8/91 (8.8) | 0.013 |
| Optic neuritis | 1/173 (0.6) | 1/82 (1.2) | 0/91 (0.0) | 0.29 |
| Reversible adverse events | 69/110 (62.7) | 25/47 (53.2) | 44/63 (69.8) | 0.07 |
| Linezolid restarted if interrupted | 24/88 (27.3) | 5/45 (11.1) | 19/43 (44.2) | <0.0001 |
| Total linezolid exposure | 143 (51–540) | 105 (0–458) | 173 (78–540) | 0.006 |
| Interruption of meropenem | 52/94 (55.3) | |||
| Interruption of meropenem due to adverse events | 8/94 (8.5) | |||
| Adverse events presumably due to meropenem | 6/93 (6.5) | |||
| Meropenem restarted if interrupted | 4/8 (50) | |||
| Total meropenem exposure | 85 (49–156) |
Data are presented as N or n/N (%) or median (interquartile range), unless otherwise stated. Denominators (N) were different among the selected variables because of missing data.